keyword
MENU ▼
Read by QxMD icon Read
search

Xelox

keyword
https://www.readbyqxmd.com/read/28687001/clinical-efficacy-of-neoadjuvant-chemotherapy-regimens-fleeox-vs-xelox-in-patients-with-initially-unresectable-advanced-gastric-cancer-a-propensity-score-analysis
#1
Yang Li, Jun Chen, Qi He, Xiang Ji, Xulin Wang, Chaogang Fan, Guoli Li
PURPOSE: This study was designed to assess the effectiveness of FLEEOX (5-Fu, leucovorin, etoposide, oxaliplatin, and epirubicin) compared with XELOX (capecitabine and oxaliplatin) as neoadjuvant chemotherapy (NAC) for initially unresectable advanced gastric cancer (AGC). METHODS: This study reviewed patients who underwent FLEEOX or XELOX for initially unresectable AGC. To reduce the bias in patient selection, we conducted propensity score match (PSM) with 1:1 ratio...
June 28, 2017: Oncotarget
https://www.readbyqxmd.com/read/28668898/clinical-study-on-the-medical-value-of-combination-therapy-involving-adoptive-immunotherapy-and-chemotherapy-for-stage-iv-colorectal-cancer-comvi-study
#2
Yoichiro Yoshida, Masayasu Naito, Teppei Yamada, Naoya Aisu, Daibo Kojima, Toshiyuki Mera, Toshihiro Tanaka, Keiko Naito, Kosei Yasumoto, Takashi Kamigaki, Shigenori Gotoh, Shohta Kodama, Yuichi Yamashita, Suguru Hasegawa
BACKGROUND: Adoptive immunotherapy for cancer has evolved through development of novel technologies for generating a large number of activated killer cells, such as αβ T-cells, γδ T-cells, and natural killer cells. There has been no prospective trial of combination therapy involving adoptive immunotherapy and first-line chemotherapy for stage IV colorectal cancer. The present pilot study aimed to evaluate the safety and feasibility of combination therapy involving adoptive immunotherapy and chemotherapy for stage IV colorectal cancer (COMVI study)...
July 2017: Anticancer Research
https://www.readbyqxmd.com/read/28668897/hepatectomy-for-liver-metastases-of-colorectal-cancer-after-adoptive-chemoimmunotherapy-using-activated-%C3%AE-%C3%AE-t-cells
#3
Fuminori Ishii, Yoichiro Yoshida, Yasushi Yamauchi, Naoya Aisu, Daibo Kojima, Toshiyuki Mera, Daisuke Kato, Toshihiro Tanaka, Keiko Naito, Kosei Yasumoto, Takashi Kamigaki, Shigenori Goto, Yoshihiro Hamada, Satoshi Nimura, Shohta Kodama, Suguru Hasegawa
BACKGROUND/AIM: Various types of chemoimmunotherapies for malignant tumors have been reported. However, there are few reports on hepatectomy after chemoimmunotherapy. We evaluated the safety and efficacy of hepatectomy for patients with stage IV colorectal liver metastases (CLM) after chemoimmunotherapy using activated αβ T-cells. PATIENTS AND METHODS: From June 2012 to December 2016, five patients who underwent hepatectomy after receiving capecitabine and oxaliplatin (XELOX) plus bevacizumab and ex vivo-expanded αβ T-lymphocytes as first-line chemoimmunotherapy were included...
July 2017: Anticancer Research
https://www.readbyqxmd.com/read/28668863/phase-i-study-of-neoadjuvant-chemotherapy-with-capecitabine-and-oxaliplatin-for-locally-advanced-gastric-cancer
#4
Hironaga Satake, Masato Kondo, Motoko Mizumoto, Takeshi Kotake, Yoshihiro Okita, Takatsugu Ogata, Yukimasa Hatachi, Hisateru Yasui, Akira Miki, Yukihiro Imai, Chihiro Ichikawa, Kenta Murotani, Masahito Kotaka, Takeshi Kato, Satoshi Kaihara, Akihito Tsuji
AIM: To determine the recommended dose of neoadjuvant chemotherapy of combined capecitabine and oxalipatin (G-XELOX) for locally advanced gastric cancer. PATIENTS AND METHODS: Patients received two cycles of neoadjuvant chemotherapy with oxaliplatin on day 1 and capecitabine (2,000 mg/m(2)/day, b.i.d.) on days 1-14, repeated every 3 weeks. They then underwent gastrectomy with curative D2/3 lymph-node dissection followed by adjuvant therapy with S-1 for 1 year. De-escalation of oxaliplatin dose was planned (starting at level 1, oxalipatin 130 mg/m(2))...
July 2017: Anticancer Research
https://www.readbyqxmd.com/read/28599498/sequential-administration-of-xelox-and-xeliri-is-effective-feasible-and-well-tolerated-by-patients-with-metastatic-colorectal-cancer
#5
Taro Fukui, Koichi Suzuki, Kosuke Ichida, Yuji Takayama, Nao Kakizawa, Yuta Muto, Fumi Hasegawa, Fumiaki Watanabe, Rina Kikugawa, Masaaki Saito, Shingo Tsujinaka, Yasuyuki Miyakura, Toshiki Rikiyama
Sequential administration of the chemotherapy regimes capecitabine and oxaliplatin (XELOX) and capecitabine and irinotecan (XELIRI) in the first- to second-line treatment setting would allow patients to be managed more easily in an outpatient unit. However, a small number of studies have raised concerns of cumulative adverse events as a consequence of the continuous use of capecitabine. To investigate this, the present study conducted a retrospective review of 81 consecutive metastatic colorectal cancer (mCRC) patients treated with the oxaliplatin, fluorouracil and leucovorin-irinotecan, fluorouracil and leucovorin (FOLFOX-FOFIRI/F-F) regimen (n=40) or the XELOX-XELIRI (X-X) regimen (n=41) in first- to second-line chemotherapy in Saitama Medical Center between 2006 and 2012...
June 2017: Oncology Letters
https://www.readbyqxmd.com/read/28553122/peripheral-venous-blood-neutrophil-to-lymphocyte-ratio-predicts-survival-in-patients-with-advanced-gastric-cancer-treated-with-neoadjuvant-chemotherapy
#6
Li Chen, Yanjiao Zuo, Lihua Zhu, Yuxin Zhang, Sen Li, Fei Ma, Yu Han, Hongjiang Song, Yingwei Xue
BACKGROUND: Accurate and useful predictors of gastric carcinoma treated with neoadjuvant chemotherapy are lacking at present. We aim to explore the potential prognostic significance of the neutrophil-to-lymphocyte ratio (NLR) in advanced gastric cancer receiving S-1 plus oxaliplatin (SOX) or oxaliplatin and capecitabine (XELOX) regimen. METHODS: We enrolled 91 patients with advanced gastric cancer treated with neoadjuvant chemotherapy from August 2008 to September 2015...
2017: OncoTargets and Therapy
https://www.readbyqxmd.com/read/28536340/-a-case-of-advanced-transverse-colon-cancer-with-nephrotic-syndrome-treated-with-curative-resection-and-complete-adjuvant-chemotherapy
#7
Nobutaka Sato, Seiya Fuyuno, Teppei Hatada, Takashi Furuhashi, Toshihiko Abe
A 74-year-old woman was diagnosed as having transverse colon cancer after diagnosis of nephrotic syndrome caused by membranous nephropathy. Although she had hypoproteinemia and hypoalbuminemia, we judged that she had no major nutritional problem. In previous, similar case reports, the use of human serum albumin and fresh-frozen plasma was suggested to be important to avoid complications in the perioperative period. Thus, we used the same in our patient in the perioperative period. In addition, we paid special attention to perioperative nutrition management and used total parenteral nutrition in perioperative period...
May 2017: Gan to Kagaku Ryoho. Cancer & Chemotherapy
https://www.readbyqxmd.com/read/28502421/is-neoadjuvant-chemoradiotherapy-always-necessary-for-mid-high-local-advanced-rectal-cancer-a-comparative-analysis-after-propensity-score-matching
#8
Y Zhang, Y Sun, Z Xu, P Chi, X Lu
AIM: This study was aimed to compare perioperative and oncological outcomes of mid/high locally advanced midrectal cancer (LARC) treated with neoadjuvant chemoradiotherapy (NCRT) vs. surgery alone, and to identify risk factors for local recurrence in mid/high LARC. METHOD: A total of 471 mid/high LARC patients treated with surgery alone or NCRT (50.4 Gy in 28 fractions) with concurrent FOLFOX/XELOX followed by TME in 6-8 weeks from 2008 to 2014 were matched 1:1 by using propensity score analysis...
May 4, 2017: European Journal of Surgical Oncology
https://www.readbyqxmd.com/read/28419993/reduction-in-peripheral-cd19-cd24hcd27-b-cell-frequency-predicts-favourable-clinical-course-in-xelox-treated-patients-with-advanced-gastric-cancer
#9
Wei Li, Dongli Song, Hong Li, Li Liang, Naiqing Zhao, Tianshu Liu
BACKGROUND: Accumulating evidence suggests that regulatory B cells (Bregs) play an important role in modulating the immune response to tumours. Our previous study indicated that a small percentage of peripheral CD19+CD24hCD27+ Breg cells slowed gastric cancer progression in XELOX-treated patients. Here, we further investigated the relationship between dynamic changes in circulating Breg cells and the clinical course in XELOX-treated gastric cancer patients. METHODS: A total of 52 patients with advanced gastric cancer were enrolled in this study...
2017: Cellular Physiology and Biochemistry
https://www.readbyqxmd.com/read/28391355/comparison-between-hypersensitivity-reactions-to-cycles-of-modified-folfox6-and-xelox-therapies-in-patients-with-colorectal-cancer
#10
COMPARATIVE STUDY
Hideki Ohta, Takahiro Hayashi, Sumie Murai, Hideyo Shiouchi, Yosuke Ando, Satomi Kumazawa, Kaori Ito, Yoshiaki Ikeda, Hiroshi Matsuoka, Kotaro Maeda, Kenji Kawada, Kimio Yasuda, Shigeki Yamada
PURPOSE: Although hypersensitivity reactions (HSRs) to oxaliplatin (L-OHP) therapy are well-documented, few reports have compared different therapies in terms of HSR occurrence. In this study, we compared the frequency and pattern of HSRs to modified FOLFOX6 (mFOLFOX6; 5-fluorouracil, levofolinate calcium and L-OHP infusions) and XELOX (capecitabine and L-OHP) therapies, and sought to identify risk factors associated with HSRs. METHODS: Patients who had received mFOLFOX6 or XELOX chemotherapeutic regimens for unresectable colon or rectal cancer or as adjuvant chemotherapy following colon cancer surgery between April 2012 and August 2015 were included...
May 2017: Cancer Chemotherapy and Pharmacology
https://www.readbyqxmd.com/read/28327986/phase-iii-trial-comparing-3-6-months-of-adjuvant-folfox4-xelox-in-stage-ii-iii-colon-cancer-safety-and-compliance-in-the-tosca-trial
#11
S Lonardi, A Sobrero, G Rosati, M Di Bartolomeo, M Ronzoni, G Aprile, B Massida, M Scartozzi, M Banzi, M G Zampino, F Pasini, P Marchetti, M Cantore, A Zaniboni, L Rimassa, L Ciuffreda, D Ferrari, S Barni, V Zagonel, E Maiello, E Rulli, R Labianca
No abstract text is available yet for this article.
February 23, 2017: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/28279170/patients-with-pathological-stage-n2-rectal-cancer-treated-with-early-adjuvant-chemotherapy-have-a-lower-treatment-failure-rate
#12
Yan-Ru Feng, Jing Jin, Hua Ren, Xin Wang, Shu-Lian Wang, Wei-Hu Wang, Yong-Wen Song, Yue-Ping Liu, Yuan Tang, Ning Li, Xin-Fan Liu, Hui Fang, Zi-Hao Yu, Ye-Xiong Li
BACKGROUND: In this era of oxaliplatin-based adjuvant therapy, the optimal sequence in which chemoradiotherapy should be administered for pathological stage N2 rectal cancer is unknown. The aim of this study was to investigate this sequence. METHODS: In the primary adjuvant concurrent chemoradiotherapy (A-CRT) group (n = 71), postoperative concurrent chemoradiotherapy was administered before adjuvant chemotherapy. In the primary adjuvant chemotherapy (A-CT) group (n = 43), postoperative concurrent chemoradiotherapy was administered during or after adjuvant chemotherapy...
March 9, 2017: BMC Cancer
https://www.readbyqxmd.com/read/28174488/a-pilot-phase-ii-study-of-neoadjuvant-triplet-chemotherapy-regimen-in-patients-with-locally-advanced-resectable-colon-cancer
#13
Haitao Zhou, Yan Song, Jun Jiang, Haitao Niu, Hong Zhao, Jianwei Liang, Hao Su, Zheng Wang, Zhixiang Zhou, Jing Huang
OBJECTIVE: This study aims to investigate the feasibility, safety and efficacy of triplet regimen of neoadjuvant chemotherapy in patients with locally advanced resectable colon cancer. METHODS: Patients with clinical stage IIIb colon cancer received a perioperative triple chemotherapy regimen (oxaliplatin 85 mg/m(2) and irinotecan 150 mg/m(2), combined with folinic acid 200 mg, 5-fluorouracil 500 mg bolus and then 2,400 mg/m(2) by 44 h infusion or capecitabine 1 g/m(2) or S-1 40-60 mg b...
December 2016: Chinese Journal of Cancer Research, Chung-kuo Yen Cheng Yen Chiu
https://www.readbyqxmd.com/read/28133349/-long-term-survival-of-a-patient-with-sigmoid-colon-cancer-with-multiple-visceral-metastases
#14
Yoshiyuki Sasaki, Naoto Nishigori, Fumikazu Koyama, Takeshi Ueda, Takashi Inoue, Keijirou Kawasaki, Shinsaku Obara, Takayuki Nakamoto, Yasuyuki Nakamura, Hisao Fujii, Yoshiyuki Nakajima
A 66-year-old woman underwent total pelvic exenteration for a pelvic tumor. The pathological diagnosis was sigmoid colon cancer T4b(in the small intestine, uterus, and vagina), N0, M0, Stage II . The patient was treated with XELOX for 6 months as adjuvant chemotherapy and was then treated with IRIS for another 6 months. Brain metastasis developed in the left occipital lobe after 12 months, and she underwent craniotomy and enucleation of the tumor. Liver metastasis and peritoneal dissemination metastasis developed 16 months after her initial diagnosis...
November 2016: Gan to Kagaku Ryoho. Cancer & Chemotherapy
https://www.readbyqxmd.com/read/28133314/-a-case-of-metastatic-lung-cancer-from-colon-cancer-with-a-long-partial-response-with-regorafenib-treatment
#15
Yasuhito Iseki, Masakazu Yashiro, Masatsune Shibutani, Hisashi Nagahara, Kiyoshi Maeda, Shinji Matsutani, Tatsuro Tamura, Go Ohira, Sadaaki Yamazoe, Kenjiro Kimura, Takahiro Toyokawa, Ryosuke Amano, Hiroaki Tanaka, Kazuya Muguruma, Kosei Hirakawa, Masaichi Ohira
A 66-year-old woman underwent sigmoidectomy for colon cancer. The final diagnosis was early cancer of pT2 pN0 and M0 (fStage I ). A chest CT revealed lung metastasis and lymph node metastasis 6 years after surgery. The patient was treated sequentially with FOLFOX, FOLFIRI, and XELOX regimens. Since these regimens resulted in progressive disease, regorafenib was started as the fourth regimen. After 8 courses, she was evaluated as having a partial response. Her partial response has continued for 18 months of regorafenib treatment...
November 2016: Gan to Kagaku Ryoho. Cancer & Chemotherapy
https://www.readbyqxmd.com/read/28133306/-effectiveness-of-irinotecan-s-1-and-bevacizumab-for-rectal-cancer-with-lung-and-skin-metastases-after-adjuvant-chemotherapy
#16
Kiyotaka Hagihara, Masataka Ikeda, Sakae Maeda, Mamoru Uemura, Kazuyoshi Yamamoto, Masakazu Miyake, Naoki Hama, Kazuhiro Nishikawa, Atsushi Miyamoto, Hideyasu Omiya, Michihiko Miyazaki, Motohiro Hirao, Koji Takami, Shoji Nakamori, Mitsugu Sekimoto
A 50-year-old woman with a chief complaint of bloody stools was diagnosed with rectal cancer via colonoscopy. Laparoscopic rectal anterior resection with D3 lymph node dissection was performed in June 2014. The pathological diagnosis was pStage III a(Ra, pT3, N1)cancer, and the patient received 8 courses of XELOX as postoperative adjuvant chemotherapy. During follow-up at 12 months after surgery, chest computed tomography revealed a mass in the left lingular segment measuring 25mm in diameter and multiple small nodules in both the lungs, indicating lung metastases...
November 2016: Gan to Kagaku Ryoho. Cancer & Chemotherapy
https://www.readbyqxmd.com/read/28133295/-a-systematic-analysis-of-oncogene-and-tumor-suppressor-genes-for-panitumumab-resistant-rectal-cancer-with-wild-ras-gene-a-case-report
#17
Yosuke Tajima, Yoshifumi Shimada, Ryoma Yagi, Takuma Okamura, Masato Nakano, Hitoshi Kameyama, Hitoshi Nogami, Satoshi Maruyama, Yasumasa Takii, Kohei Miura, Hiroshi Ichikawa, Masayuki Nagahashi, Jun Sakata, Takashi Kobayashi, Toshifumi Wakai
A 58-year-old man was admitted with the complaint of bloody stools. Colonoscopy and computed tomography revealed a rectal cancer with a liver metastasis and multiple lung metastases. After administering a regimen comprising 3 courses of XELOX plus bevacizumab chemotherapy, the sizes of the primary and metastatic lesions decreased remarkably. Abdominoperineal resection was performed for local control of the cancer; the specimen from the initial tumor was found to be KRAS wild type. After 14 courses of XELOX chemotherapy, brain metastases were detected...
November 2016: Gan to Kagaku Ryoho. Cancer & Chemotherapy
https://www.readbyqxmd.com/read/28133255/-a-case-report-of-clinical-complete-response-with-chemotherapy-for-descending-colon-cancer-complicated-with-severe-pulmonary-dysfunction
#18
Hidehiko Uno, Takashi Shida, Takeshi Ogasawara, Satoru Nomura, Yoshihiro Takahara, Yoshiharu Sato, Teisuke Komatu, Makoto Takahashi
A 76-year-old male patient was diagnosed with progressive descending colon cancer. Since the patient had severe respiratoryfunction impairment after right pneumonectomy, the anesthesiologydepartment of our hospital determined that general anesthesia induction was too difficult. He was thus started on capecitabine plus oxaliplatin(XELOX)therapy. Three months after starting this treatment, colonoscopyshowed that the site had become scarred, and tissue examination revealed no indication of malignancy. Accordingly, the patient achieved clinical complete response...
November 2016: Gan to Kagaku Ryoho. Cancer & Chemotherapy
https://www.readbyqxmd.com/read/28133252/-a-case-of-locally-far-advanced-colon-cancer-resected-by-laparoscopic-surgery-after-colonic-stent-insertion-and-neoadjuvant-chemotherapy
#19
Yasushi Ishii, Yosuke Hirano, Taro Munechika, Keita Tanaka, Yoshihiro Yonemitsu, Masako Nomi, Ryosuke Shibata, Tatsuya Okamoto, Hiroshi Maeno, Jun Yanagisawa, Shunji Kawamoto, Tomoaki Noritomi
We report a case of locally far-advanced colon cancer resected by laparoscopic surgery after colonic stent insertion and neoadjuvant chemotherapy. A 71-year-old man with obstructive symptoms was admitted to our hospital in July 2015. CT revealed a sigmoid colon tumor infiltrating the retroperitoneum and small intestine. Lower gastrointestinal endoscopy showed a sigmoid colon cancer. Self-expandable metallic stent insertion for obstructive colon cancer alleviated the patient's symptoms quickly. Four courses of neoadjuvant chemotherapy(XELOX)reduced the primary tumor in size, allowing for laparoscopic surgical resection...
November 2016: Gan to Kagaku Ryoho. Cancer & Chemotherapy
https://www.readbyqxmd.com/read/28133250/-a-successful-case-of-conversion-therapy-after-chemotherapy-for-advanced-rectal-cancer-with-inguinal-lymph-node-metastasis
#20
Jun Sato, Hideaki Karasawa, Shimpei Maeda, Shinobu Ohnuma, Kazuhiro Watanabe, Munenori Nagao, Tomoya Abe, Hiroaki Musha, Fuyuhiko Motoi, Takeshi Naitoh, Michiaki Unno
A70-year-old man was diagnosed with lower rectal cancer with right inguinal lymph node metastasis. Surgical resection was not suitable for this patient. Chemotherapy(IRIS plus bevacizumab followed by XELOX plus bevacizumab)was administered for 16 months. After the chemotherapy, the rectal tumor and lymph node swelling were significantly reduced and distant metastasis was not observed on CT scans. Therefore, the tumor was considered to be resectable and abdominoperineal resection of the rectum with lymph node dissection was performed...
November 2016: Gan to Kagaku Ryoho. Cancer & Chemotherapy
keyword
keyword
2278
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"